mHealth Facilitated Intervention to Improve HIV Pre-Exposure Prophylaxis

Status Withdrawn

Clinical Trial Summary

If taken every day, PrEP is an effective method for preventing HIV. However, many prescribed PrEP in the U.S. do not take it every day, as prescribed. The goal of this study is to develop and test an intervention, facilitated by a mobile app, meant to improve adherence to PrEP. To that end, 60 individuals prescribed PrEP who do not take their PrEP every day as prescribed will be recruited. Participants will complete an initial research interview, receive a one-on-one PrEP adherence session with an adherence coach, and complete follow-up interviews at 1, 3, 6, and 12 months. In addition, some participants will be randomized to receive access to a mobile app and adherence coaching via the app for 12-months. The primary outcome is self-reported adherence to PrEP. This study will examine whether this intervention is effective at improving adherence to PrEP, is feasible to use, and found acceptable by those who use it.

Clinical Trial Description

HIV pre-exposure prophylaxis (PrEP), involves the use of antiretroviral (ART) medications (Truvada or Descovy) by persons uninfected with HIV to prevent HIV acquisition. The efficacy of PrEP for preventing HIV acquisition is highly impacted by one's medication adherence. Within the U.S., adherence to PrEP is suboptimal. Commonly cited barriers to PrEP adherence include forgetfulness, low HIV risk perception, stigma, and cost. There is a need for interventions that improve adherence to PrEP, are readily disseminable, and that make efficient use of resources. To that end the current project will examine the feasibility, acceptability, and preliminary efficacy of an intervention tailored for PrEP adherence, facilitated by mHealth. Individuals prescribed PrEP (n = 60) who report taking, on average, fewer than 6 doses per week in the past month will be recruited. Participants will be randomly assigned to the intervention (Carium) or control condition. Data collection will consist of a baseline interview and follow-ups at 1, 3, 6, and 12 months. The primary outcome is PrEP adherence. PrEP adherence will be measured via self-report, pill counts, and use of a urine test developed by UrSure. The urine test is for research use only and will only be used to detect the presence of PrEP in urine if participants self-report taking PrEP in the last 48 hours. It is expected that participants in the Carium condition, relative to control, will report better adherence to PrEP. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04990583
Study type	Interventional
Source	Rhode Island Hospital
Contact
Status	Withdrawn
Phase	N/A
Start date	March 1, 2021
Completion date	July 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04709640` - Pilot Study to Improve Medication Management in Older Adults	N/A
Completed	`NCT03257579` - Myocardial Infarction Prescription Duration Adherence Study	N/A
Completed	`NCT05376397` - Testing THRIVE 365 for Black Sexual Minority Men (On The Daily)	N/A
Withdrawn	`NCT03427008` - A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients	N/A
Completed	`NCT03805451` - Life Steps for PrEP for Youth	N/A
Withdrawn	`NCT03292393` - Social Norms and Antihypertensive Medication Adherence	N/A
Completed	`NCT02914730` - Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
Completed	`NCT02823795` - The Supporting Patient Activation in Transition to Home Intervention	N/A
Not yet recruiting	`NCT02876848` - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)	N/A
Completed	`NCT02066935` - Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study
Completed	`NCT02797262` - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System	N/A
Completed	`NCT01934608` - The Effect of Synching Prescription Refills on Adherence	N/A
Completed	`NCT01770314` - Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.	Phase 2
Completed	`NCT01741311` - Secondary HIV Prevention and Adherence Among HIV-infected Drug Users	N/A
Recruiting	`NCT01105104` - An Enhanced Medication Monitoring Program	Phase 1
Completed	`NCT01859273` - Adherence Enhancement for Renal Transplant Patients	N/A
Withdrawn	`NCT01430702` - Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults	N/A
Completed	`NCT01118208` - Blister Packaging Medication to Increase Treatment Adherence and Clinical Response	N/A
Completed	`NCT00848224` - Improving Adherence to Pharmacological Treatment	N/A
Recruiting	`NCT06034301` - Pill Bottle vs Reminder App	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

mHealth Facilitated Intervention to Improve HIV Pre-Exposure Prophylaxis Adherence — SMART PrEP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms